CSL Behring
Privately held: no public share price
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
etranacogene dezaparvovec(Hemgenix) | Approved | Factor IX gene delivery (hFIX-Padua)Gene therapy / editing | Hemophilia B |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
October 2028 (1)
Est. primary completion 2028-10-04 · NCT06003387 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.